Genotoxicity Genotype Marketing Protein 
The Pharma Data
MARCH 25, 2021
SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.
The Pharma Data
APRIL 7, 2021
Trodelvy is directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. months vs. 6.9
Expert insights. Personalized for you.
52 
Let's personalize your content